Patent classifications
C07D267/16
MACROCYCLIC-2-AMINO-3-FLUORO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1
##STR00001##
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds (formula (I)), and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
MACROCYCLIC-2-AMINO-3-FLUORO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1
##STR00001##
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds (formula (I)), and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein
The disclosure is directed to compounds of Formula I
##STR00001##
Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein
The disclosure is directed to compounds of Formula I
##STR00001##
Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES
Tricyclic compounds, and in particular novel dibenzoxazepin derivates are disclosed herein, which were quite surprisingly found as having OMA1 and/or OPA1 modulatory properties. Compounds of present invention may provide useful for the treatment of certain conditions and diseases, which are amenable to OMA1 and/or OPA1-modulatory therapies. Such conditions may include conditions and diseases prevalent in the elderly, including cancer. Pharmaceutical compositions comprising compounds of present invention may be combined with other treatments or further comprise other pharmaceutically active ingredients.
TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES
Tricyclic compounds, and in particular novel dibenzoxazepin derivates are disclosed herein, which were quite surprisingly found as having OMA1 and/or OPA1 modulatory properties. Compounds of present invention may provide useful for the treatment of certain conditions and diseases, which are amenable to OMA1 and/or OPA1-modulatory therapies. Such conditions may include conditions and diseases prevalent in the elderly, including cancer. Pharmaceutical compositions comprising compounds of present invention may be combined with other treatments or further comprise other pharmaceutically active ingredients.
Synthesis of vinylic alcohol intermediates
Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound (E), wherein R.sup.1 is described herein. Compound (E) can be useful in synthesizing compound (A1), or a salt or solvate thereof, and compound (A2), or a salt of solvate thereof.
Ring Closing Synthesis of Macrocyclic MCL-1 Inhibitor Intermediates
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound F that can be used to prepare them where the variable PG is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof and compound A2, and salts and solvates thereof.
##STR00001##
Ring Closing Synthesis of Macrocyclic MCL-1 Inhibitor Intermediates
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound F that can be used to prepare them where the variable PG is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof and compound A2, and salts and solvates thereof.
##STR00001##
Processes and intermediates for preparing MCL1 inhibitors
The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.